Atrium Medical’s covered versus balloon expandable stent trial (COBEST) demonstrated positive results of Atrium’s proprietary balloon expandable covered stent technology over traditional bare metal stents (BMS) for the treatment of peripheral arterial disease (PAD).

An independent landmark prospective multicentre randomised controlled COBEST trial showed that patients implanted with Atrium’s Advanta V12 were more likely to remain free from binary restenosis and have fewer reinterventions than patients implanted with BMS.

The Advanta Vascular V12 covered stent is a low profile, pre-mounted covered stent made of a radial expandable stainless steel that is completely encapsulated with Atrium’s patented one-piece covering technology.

The trial showed Vascular V12 produced lower restenosis rates, target vessel revascularization (TVR) rates, improved ABI’s, long term patency and clinical outcomes compared to BMS.

Royal Perth Hospital in Perth, Australia, head of vascular surgery Mwipatayi said the striking result from the COBEST study was the five-times lower TVR rate with Atrium’s V12 when compared to BMS.

Atrium’s Vascular V12 showed benefit in patients with more complex disease (TASC C & D lesions).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.